Resource library - Median Technologies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

Elton Rexhepaj [1], Corinne Ramos [1], Yan Liu [1], Benoit Huet [1], Olivier Lucidarme [2], Nozha Boujemaa [1] – Affiliations: [1] Median Technologies, Valbonne, France - [2] Hôpital Universitaire Pitié-Salpêtrière-APHP, Paris, France

Poster presented at the Digital International Liver Congress – EASL – August 27-29, 2020

Hepatic fibrosis diagnosis is important for risk stratification, prognosis evaluation and monitoring of treatment response. Using computer tomography (CT) perfusion imaging and splenic radiomics, the objective of this study is to validate the use this non-invasive fibrosis scoring method to identify patients whose tumors are at high risk of recurrence after hepatic resection.